Trial Profile
A multicenter, open-label, follow-up trial evaluating the long-term safety of levetiracetam individualized dose from 1000 to 3000 mg/day (oral tablets of 500 mg b.i.d.), used as monotherapy in subjects (at least 16 years) suffering from epilepsy and coming from the N01061 or the N01093 trials.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2018
Price :
$35
*
At a glance
- Drugs Levetiracetam (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors UCB Pharma Inc
- 06 Jul 2007 Status changed from in progress to completed.
- 14 Nov 2005 New trial record.